Vardenafil (Levitra/Staxyn): How It Works, Who It Helps, and When Injection Therapy Is the Better Option

Does Vardenafil Come in an Injectable Form?

No. Vardenafil has no approved or commercially available injectable formulation. The FDA has approved vardenafil only as a film-coated oral tablet (Levitra, 5 mg / 10 mg / 20 mg) and as an orally disintegrating tablet (Staxyn, 10 mg). Compounding pharmacies have not established a safe, stable parenteral version of vardenafil, and no phase III trial data support intravenous or intracavernosal use of the drug.

When a patient or clinician refers to "vardenafil self-injection technique," they are almost always asking one of two questions: either how vardenafil works mechanistically at the smooth-muscle level (a question about injection-like precision), or what a man should do when oral PDE5 inhibitors stop working and injection therapy becomes the next step. Both questions deserve a careful answer.

Why the "Self-Injection" Question Keeps Coming Up

Men with severe erectile dysfunction (ED) who research treatment options often encounter intracavernosal injection (ICI) therapy alongside PDE5 inhibitor information on the same pages. The overlap creates confusion. PDE5 inhibitors such as vardenafil, sildenafil, and tadalafil work through the same nitric oxide (NO) pathway that ICI agents exploit, just at a different point in the cascade.

Understanding that shared pathway makes it easier to appreciate why one approach may succeed after the other fails.

How Vardenafil Works: The PDE5 Mechanism

Vardenafil produces erections by amplifying a signal the body already generates during sexual arousal. It does not create arousal on its own.

The Nitric Oxide Cascade

During sexual stimulation, non-adrenergic, non-cholinergic (NANC) neurons and vascular endothelial cells release nitric oxide (NO) into the corpus cavernosum. NO activates soluble guanylate cyclase, which converts GTP to cyclic guanosine monophosphate (cGMP). Elevated cGMP relaxes cavernosal smooth muscle by lowering intracellular calcium, which allows arterial inflow and veno-occlusion to produce a rigid erection. Phosphodiesterase type 5 (PDE5) is the enzyme that degrades cGMP back to the inactive GMP, terminating the erection.

Vardenafil binds competitively and selectively to the catalytic site of PDE5. By blocking cGMP breakdown, it extends and amplifies the smooth-muscle relaxation that sexual arousal initiated. No arousal means minimal NO release, which is why vardenafil does not produce erections in the absence of stimulation.

Selectivity Profile and Why It Matters Clinically

PDE5 is expressed most densely in cavernosal smooth muscle, pulmonary vasculature, and platelets. Vardenafil's IC50 for PDE5 is approximately 0.7 nM, roughly 15 times more selective for PDE5 than sildenafil in direct binding assays. Its IC50 for PDE6 (the retinal isoform responsible for the blue-tinge visual disturbance seen with sildenafil) is substantially higher, which is why vardenafil causes fewer visual side effects at therapeutic doses.

The selectivity for PDE5 over PDE1 (cardiac isoform) is also high, theoretically reducing the risk of QTc prolongation, though post-marketing reports prompted FDA label updates requiring caution in men with congenital long-QT syndrome.

Pharmacokinetics in Plain Terms

| Parameter | Vardenafil (tablet) | Vardenafil (Staxyn ODT) | |---|---|---| | Tmax | 0.7-0.9 hours | 1.0-1.5 hours (slightly slower) | | Bioavailability | ~15% (first-pass) | Not bioequivalent to tablet; do not substitute mg-for-mg | | Half-life | 4-5 hours | 4-5 hours | | Effect of high-fat meal | Delays Tmax by ~1 hour | Less food-sensitive | | CYP450 metabolism | CYP3A4 primary | CYP3A4 primary |

The practical takeaway: men who eat a large meal before sex should take vardenafil 60 minutes ahead rather than 30, or consider Staxyn ODT, which dissolves sublingually and bypasses some first-pass delay.

Clinical Evidence: What the Trials Actually Show

Porst et al. 2003: Diabetic ED

The most cited vardenafil trial in populations with difficult-to-treat ED is Porst et al. (2003, Int J Impot Res), a randomized, double-blind, placebo-controlled study examining vardenafil in men with type 1 and type 2 diabetes-related ED. In that trial, vardenafil 10 mg and 20 mg produced statistically significant improvements in the International Index of Erectile Function (IIEF) erectile function domain score compared to placebo (P<0.001), with 57% of 10 mg and 72% of 20 mg patients reporting improved erections versus 13% placebo. Diabetic ED is notoriously resistant to treatment because autonomic neuropathy reduces NO release and endothelial dysfunction lowers baseline cGMP production, so demonstrating efficacy in this population is clinically meaningful.

Broader Phase III Data

A pooled analysis of three phase III trials (N=1,112) published in Urology showed that vardenafil 10 mg and 20 mg improved IIEF erectile function domain scores by 7.0 and 8.7 points respectively, versus 1.9 points for placebo. Successful intercourse rates were 65-80% across dose groups versus 32% placebo. These numbers are consistent with findings for sildenafil and tadalafil, confirming that within the PDE5 inhibitor class, efficacy differences are modest and patient-specific factors (timing, food, anxiety) often matter more than which molecule is chosen.

Cardiovascular Safety

The Princeton Consensus III guidelines stratify men with cardiovascular disease into low, intermediate, and high risk before prescribing PDE5 inhibitors. Men in the low-risk category (stable angina, controlled hypertension, mild valvular disease) can receive vardenafil safely. The absolute contraindication is concurrent use of any organic nitrate, including sublingual nitroglycerin, because the combination produces severe hypotension that can be fatal.

When Oral PDE5 Inhibitors Fail: The Case for Injection Therapy

Approximately 30-35% of men with ED do not respond adequately to oral PDE5 inhibitors. A 2010 review in the Journal of Sexual Medicine identified the following as the strongest predictors of PDE5 inhibitor failure: radical prostatectomy (bilateral nerve damage), poorly controlled diabetes with autonomic neuropathy, pelvic radiation, and severe vascular disease with DICP (deep internal cavernous pressure) dysfunction. For these men, intracavernosal injection (ICI) therapy is the most effective non-surgical option.

What Intracavernosal Injection Therapy Is

ICI delivers vasodilating agents directly into the corpus cavernosum, bypassing the NO-cGMP pathway entirely in some cases. The erection is produced by smooth-muscle relaxation driven by:

• Alprostadil (PGE1): Binds EP2/EP3 receptors, raises intracavernosal cAMP, relaxes smooth muscle. FDA-approved as Caverject (Pfizer) and Edex (Endo Pharmaceuticals).
• Papaverine: Non-selective PDE inhibitor that raises both cAMP and cGMP.
• Phentolamine: Alpha-1 and alpha-2 adrenergic blocker, reduces sympathetic vasoconstriction.
• Trimix: A combination of all three agents, compounded by specialty pharmacies and widely used off-label for refractory ED.

These agents work even when NO release is absent, making ICI effective in men whose oral PDE5 inhibitors have completely failed. The AUA Erectile Dysfunction Guideline (2018, amended 2022) rates ICI with alprostadil as a standard second-line treatment with strong evidence, noting response rates of 70-90% across etiologies.

Self-Injection Technique: Step-by-Step Clinical Protocol

The following protocol reflects standard clinical teaching used in urology training programs and outpatient andrology clinics. The first injection is always performed under physician supervision. Men train over one to three in-office sessions before injecting at home.

Equipment needed:

• 27-gauge or 29-gauge, 0.5-inch (12.7 mm) insulin syringe
• Prescribed medication (alprostadil vial or trimix syringe from pharmacy)
• Alcohol swabs
• Gauze or cotton ball
• Sharps disposal container

Step 1: Wash hands thoroughly. Use soap and warm water for at least 20 seconds. Gloves are not required at home but reduce contamination risk.

Step 2: Prepare the medication. If using a multi-dose vial, wipe the rubber stopper with an alcohol swab. Draw the prescribed dose (typically 2.5-20 mcg for alprostadil; trimix doses vary by compounded concentration). Tap the syringe to remove air bubbles. Your prescribing physician will set the starting dose low and titrate up over two to three office visits before authorizing home use.

Step 3: Identify the injection site. Grasp the glans with the non-dominant hand and stretch the penis slightly. The correct injection site is the lateral aspect of the penile shaft, at the 3 o'clock or 9 o'clock position, in the proximal to middle third of the shaft. Avoid the 12 o'clock position (dorsal neurovascular bundle) and the 6 o'clock position (urethra).

Step 4: Cleanse the site. Wipe with an alcohol swab and allow to dry for 10 seconds. Wet alcohol on the skin stings unnecessarily and may introduce moisture to the injection site.

Step 5: Inject. Hold the syringe like a dart, perpendicular (90 degrees) to the penile shaft. Insert the needle fully into the lateral corpus cavernosum with a single smooth motion. Do not angle. Aspirate briefly (1-2 seconds) to confirm you are not in a vessel. Inject the medication slowly over 5-10 seconds.

Step 6: Withdraw and apply pressure. Remove the needle in the same angle it entered. Press a gauze or cotton ball firmly against the site for 1-2 minutes. This prevents hematoma formation, the most common minor complication.

Step 7: Alternate sides. Each injection should use the contralateral lateral aspect to the previous one, rotating to prevent fibrotic nodule formation (a late complication of repeated trauma to the same site).

Onset and duration: Erections typically begin within 5-15 minutes. Alprostadil erections last 30-60 minutes. Trimix erections may last longer; the prescribing dose is titrated to achieve erections that resolve within 60 minutes.

Frequency limits: No more than one injection per 24-hour period and no more than three injections per week. Exceeding these limits increases the risk of priapism and fibrosis.

Priapism: Recognizing and Managing the Key Risk

Priapism (erection lasting more than 4 hours) occurs in roughly 1-5% of ICI users, most often during dose titration. A 2013 review in the Journal of Sexual Medicine found that the risk is highest with trimix and lowest with alprostadil monotherapy. Men must have a clear written protocol before starting ICI:

• At 3 hours with no resolution, apply an ice pack to the perineum for 10 minutes.
• At 4 hours with no resolution, go to the emergency department immediately.
• Never drive to the ER alone with a pharmacologic priapism.

Emergency treatment is intracavernosal phenylephrine (100-500 mcg every 3-5 minutes), which is highly effective when administered promptly. Surgical shunting is required in fewer than 5% of priapism episodes when treatment is sought within 4-6 hours.

Vardenafil vs. Injection Therapy: A Clinical Decision Framework

The choice between oral vardenafil and ICI is not about which option is stronger. It is about matching the treatment to the physiology of the individual patient.

| Clinical Scenario | Preferred First Step | Rationale | |---|---|---| | Mild to moderate ED, intact nerves | Vardenafil 10 mg on-demand | Sufficient NO release for PDE5 amplification | | Post-radical prostatectomy (nerve-sparing) | Vardenafil + penile rehab protocol | Some nerve function preserved; early use may aid recovery | | Post-radical prostatectomy (non-nerve-sparing) | ICI with alprostadil or trimix | NO pathway largely absent; oral PDE5 inhibitors typically ineffective | | Diabetic ED, adequate glycemic control | Vardenafil 10-20 mg | Porst et al. 2003 demonstrated efficacy at both doses | | Diabetic ED, neuropathy, PDE5 failure | ICI trimix | Bypasses NO dependence entirely | | Pelvic radiation ED | ICI | Vascular and neurogenic damage reduces PDE5 response | | Nitrate use (any formulation) | ICI (after cardiac clearance) | Absolute contraindication to all PDE5 inhibitors |

The American Urological Association's 2022 ED guideline update states: "Physicians should offer intracavernosal injection therapy to patients who fail, cannot tolerate, or have contraindications to oral phosphodiesterase inhibitors." This is not a fallback position but an established second-line standard with decades of safety data.

Combining Vardenafil and ICI: Is There Evidence?

Some andrologists use low-dose vardenafil alongside low-dose ICI in men with partial PDE5 response who need additional effect without increasing injection dose (and therefore priapism risk). A small randomized crossover study (N=40) published in BJU International in 2006 found that the combination of sildenafil (the closest studied analog) with low-dose intracavernosal alprostadil produced higher IIEF scores and required lower alprostadil doses than either agent alone. No equivalent vardenafil-plus-ICI RCT exists, but the mechanism is plausible: vardenafil raises cGMP while alprostadil raises cAMP, targeting two separate intracellular pathways that both converge on smooth-muscle relaxation.

This combination approach must be managed by a urologist experienced in ICI therapy. Dose titration is more complex, and the risk of prolonged erection increases when two vasodilatory mechanisms are active simultaneously.

Side Effects and Drug Interactions

Common Side Effects of Vardenafil

Headache (15-21%), flushing (11-13%), nasal congestion (9-11%), and dyspepsia (4-8%) are the most frequently reported adverse events in phase III data. These are dose-dependent and generally resolve within 2-4 hours, consistent with the drug's half-life.

Back pain, reported with tadalafil (PDE11 inhibition in muscle tissue), is less common with vardenafil because vardenafil has lower affinity for PDE11.

Key Drug Interactions

Nitrates (absolute contraindication): Isosorbide mononitrate, isosorbide dinitrate, sublingual nitroglycerin, nitroglycerin patches, amyl nitrite ("poppers"). Any co-administration may produce a drop in systolic blood pressure exceeding 50 mmHg, leading to syncope, myocardial infarction, or death.

Alpha-blockers: Co-administration with tamsulosin or other alpha-blockers requires dose separation of at least 6 hours and a starting vardenafil dose of 5 mg. The FDA labeling for Levitra specifies that the 5 mg starting dose should be used when vardenafil is combined with alpha-blockers.

CYP3A4 inhibitors: Ketoconazole 400 mg raised vardenafil AUC by 10-fold in pharmacokinetic studies. Ritonavir (HIV protease inhibitor) increased vardenafil AUC 49-fold, making co-administration contraindicated. Erythromycin and clarithromycin require dose reduction to 5 mg maximum.

Common Side Effects of ICI Therapy

Penile pain after alprostadil injection is the most frequently reported ICI side effect, occurring in 11-44% of patients. A systematic review in the Journal of Sexual Medicine (2010) found that pain scores were significantly lower with trimix than alprostadil monotherapy, likely because the papaverine and phentolamine components in trimix allow lower alprostadil doses while maintaining efficacy.

Hematoma at the injection site occurs in roughly 3-5% of injections and resolves without treatment in most cases. Penile fibrosis (Peyronie's-like plaques at injection sites) occurs in fewer than 2% of patients who rotate sites correctly and stay within the recommended frequency limits.

Starting Vardenafil: Dosing and Practical Tips

The standard starting dose is 10 mg, taken 30-60 minutes before anticipated sexual activity. If the response is insufficient after at least four attempts under similar conditions (timing, arousal, no heavy meal), the prescribing physician may increase to 20 mg. Men over 65 or those with moderate hepatic impairment (Child-Pugh B) start at 5 mg.

Staxyn (10 mg ODT) dissolves on the tongue without water in approximately 30 seconds. It reaches therapeutic plasma levels slightly more slowly than the tablet, but the ODT formulation is preferred by men who find tablet-swallowing inconvenient or who anticipate activity in settings where water is not readily available. Because Staxyn is not bioequivalent to Levitra tablet at the same milligram dose, the two formulations should not be interchanged by a pharmacist without a prescriber note.

Vardenafil is not approved for daily dosing the way tadalafil 2.5-5 mg is. On-demand dosing is the only approved regimen.

Monitoring and Follow-Up

After starting vardenafil, a follow-up at 4-6 weeks allows the prescriber to assess response, adjust dose, and screen for any adverse events. Men who report chest pain, sudden vision or hearing changes, or erections lasting more than 4 hours need same-day evaluation.

For men on ICI therapy, follow-up at 1 month and then every 6 months is standard. The prescriber checks for:

• Penile nodules or plaques (fibrosis)
• Deviation or curvature changes
• Hematoma frequency
• Continued appropriate dose (neither too low for efficacy nor high enough to risk priapism)

Hemoglobin A1c, testosterone, and lipid panel should be checked in any man presenting with new ED, as these metabolic factors directly affect both the oral and injection response. Low testosterone reduces NO synthase expression; treating hypogonadism to a total testosterone above 300 ng/dL may restore or improve PDE5 inhibitor response without changing the drug or dose.